Department of General Surgery, Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang, Hebei, P.R. China.
Department of Obstetrics, Hebei General Hospital, Shijiazhuang, Hebei, P.R. China.
Immunol Invest. 2022 Jul;51(5):1302-1312. doi: 10.1080/08820139.2021.1936011. Epub 2021 Jun 3.
Genetic variants in the T cell immunoglobulin and mucin domain-containing molecule 3 () gene have been reported to be associated with the risk of cancers and patients' outcomes. The aims of this study were to explore the role of polymorphisms in the risk of colorectal cancer (CRC) and the prognosis of CRC patients in a northern Chinese population.
Two polymorphisms of were genotyped using polymerase chain reaction and ligase detection reaction in 364 CRC patients and 372 healthy control subjects. The levels of mRNA were investigated in 65 CRC tissues by quantitative real-time PCR.
The results showed that neither rs10053538 nor rs10515746 was associated with susceptibility to CRC. However, the CA+AA genotypes of rs10053538 were related to an advanced clinical stage and increased risk of lymph nodemetastasis ( = .046 and 0.024, respectively). Multivariate analyses performed after adjusting for clinical variables showed that patients with the CA+AA genotypes of rs10053538 exhibited a significantly shorter disease-free survival (DFS) and overall survival (OS) time compared with those carrying the CC genotype (HR = 1.91, 95% CI = 1.04-3.51; HR = 2.61, 95% CI = 1.35-5.03). In addition, the expression of mRNA was significantly increased in the CRC tissues of patients carrying the rs10053538 CA+AA genotypes compared with patients carrying the CC genotype ( = .019).
The rs10053538 may serve as an independent molecular marker for predicting the clinical outcome of CRC patients in the study population.
T 细胞免疫球蛋白和粘蛋白结构域 3（）基因中的遗传变异与癌症风险和患者预后相关。本研究旨在探讨在中国北方人群中，多态性与结直肠癌（CRC）风险和 CRC 患者预后的关系。
采用聚合酶链反应和连接酶检测反应对 364 例 CRC 患者和 372 例健康对照者的进行基因分型。采用实时定量 PCR 检测 65 例 CRC 组织中 mRNA 的水平。
结果显示，rs10053538 和 rs10515746 均与 CRC 易感性无关。然而，rs10053538 的 CA+AA 基因型与晚期临床分期和淋巴结转移风险增加相关（=0.046 和 0.024）。经临床变量校正的多变量分析显示，与携带 CC 基因型的患者相比，携带 rs10053538 的 CA+AA 基因型的患者无病生存期（DFS）和总生存期（OS）明显缩短（HR=1.91，95%CI=1.04-3.51；HR=2.61，95%CI=1.35-5.03）。此外，与携带 CC 基因型的患者相比，携带 rs10053538 的 CA+AA 基因型的患者 CRC 组织中 mRNA 的表达明显增加（=0.019）。
rs10053538 可作为研究人群中预测 CRC 患者临床结局的独立分子标志物。
